Depression is one of the most prevalent and debilitating conditions in modern medicine, and one of the most pharmacologically undertreated. A substantial proportion of patients with depression do not achieve full remission on SSRIs, and many more experience partial responses or adverse effects that limit long-term use. Understanding why requires looking beyond neurotransmitter imbalance to the upstream biological drivers that often underlie depressive states.
This guide is not a recommendation to stop antidepressant medications. It is an evidence-grounded discussion of how hormonal deficits, chronic inflammation, and peptide interventions intersect with mood and depression biology.
The Upstream Biology of Depression
The monoamine hypothesis of depression (low serotonin, low noradrenaline) remains the basis of most pharmaceutical treatments. But the evidence for a more complex, multi-system picture has accumulated significantly:
- Inflammatory hypothesis: Multiple studies show elevated inflammatory cytokines (IL-6, TNF-alpha, CRP) in depressed patients. Anti-inflammatory interventions show antidepressant effects in some patient subgroups. Chronic inflammation directly impairs serotonin synthesis (by shunting tryptophan toward kynurenine rather than serotonin).
- HPA axis dysregulation: Cortisol hypersecretion in chronic stress causes hippocampal neuronal damage, reduces BDNF expression, and directly suppresses serotonin receptor sensitivity.
- Low testosterone: Men with low testosterone have significantly elevated rates of depression. Testosterone has direct effects on serotonin receptors, dopamine synthesis, and BDNF expression. Treating low testosterone often substantially improves depressive symptoms in men.
- Low IGF-1: IGF-1 stimulates hippocampal neurogenesis, which is increasingly understood as a mechanism of antidepressant action. Low IGF-1 (from GH axis decline) reduces this neurogenic capacity.
- Thyroid dysfunction: Subclinical hypothyroidism is a common and frequently missed cause of depression, anxiety, and cognitive slowing.
Peptides With Evidence for Depression-Related Applications
BPC-157: Gut-Brain Axis and Neurological Protection
BPC-157 has shown antidepressant-like effects in multiple animal models of depression and stress-induced behavioural changes. Its relevant mechanisms:
- Dopaminergic neuroprotection: BPC-157 protects dopaminergic neurons from toxic damage and restores dopamine function in stress models
- Serotonin metabolism modulation: BPC-157 influences serotonin synthesis and receptor expression
- Gut-brain axis: The gut-brain connection is increasingly recognised in depression. BPC-157's original application was gastrointestinal healing, and its effects on gut permeability and vagal nerve signalling have indirect mood-relevant effects
- Anti-inflammatory: BPC-157's systemic anti-inflammatory effects reduce the neuroinflammatory burden associated with depression
Selank: Direct Anxiolytic and Mood-Stabilising Effects
Selank modulates serotonin metabolism, GABA function, and BDNF expression, addressing multiple depression-relevant neurotransmitter systems. Its mood-stabilising effects are well-characterised in Russian clinical literature.
GH Peptides: Restoring IGF-1 and BDNF
CJC-1295 and ipamorelin restore IGF-1 to physiological levels, supporting hippocampal neurogenesis and BDNF expression. Patients on GH peptide programs frequently report improved mood and reduced depressive symptoms as a component of their overall program response, reflecting the direct neurological effects of normalised IGF-1.
Addressing Testosterone Deficiency
For men with confirmed low testosterone and co-existing depression, treating the testosterone deficiency is often the most impactful mood intervention. Kisspeptin and enclomiphene restore endogenous testosterone production, addressing this common hormonal driver of male depression.
What Peptide Therapy Cannot Replace
Peptide therapy is not a replacement for:
- Established antidepressant treatment in patients with moderate to severe clinical depression
- Psychological therapy (CBT, MBSR, and other evidence-based psychotherapies have strong trial evidence for depression)
- Crisis intervention for acute suicidality or severe depressive episodes
The role of peptide therapy in depression is addressing the biological upstream factors that conventional antidepressants do not target, either as an adjunct to existing treatment or as part of a comprehensive biological medicine approach for patients whose depression has identifiable hormonal and inflammatory contributors.
The Longegra Approach to Mood and Depression
Longegra's mood programs begin with a biomarker assessment that includes:
- Total and free testosterone
- Cortisol (morning and, in some cases, 24-hour)
- IGF-1
- Thyroid panel (TSH, free T3, free T4)
- Inflammatory markers (hsCRP, IL-6)
- Vitamin D (low vitamin D is independently associated with depression)
This panel identifies whether a hormonal or inflammatory component is contributing to the patient's mood state, guiding a protocol that addresses those specific findings.
Frequently Asked Questions (FAQs)
Physician assessment of concurrent medications is required. BPC-157 and GH peptides do not have known interactions with standard antidepressants. Selank requires careful assessment in patients on SSRIs, SNRIs, or MAOIs due to its serotonergic activity. Your Longegra physician will review your full medication list before making recommendations.
